Menveo is supplied to providers in two vials that must be combined before administration. A CDC examination of the Vaccine Adverse Event Reporting System database for reports on Menveo between March 1, 2010, and Sept. 22, 2015, revealed 390 reports of administration of only one component of the vaccine to a total of 407 recipients.
Of the 407 recipients, 346 (85 percent) experienced no adverse event. Those who did experience adverse effects typically reported redness, fever and pain.
The CDC discovered similar administration errors with Pentacel, another vaccine packaged as separate components.
To avoid future incidents, the CDC recommends providers follow the instructions provided with Menveo, including the vaccine labeling, packaging and product insert.
More articles on vaccines:
Ethnic background a factor in patient response to flu vaccine, study suggests
Herpesvirus CMV-based vaccine provides protection against Ebola, study finds
Johns Hopkins study finds expanding vaccines would be an ‘excellent investment’
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
